Paraganglioma (Glomus Jugulare Tumor) is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for Paraganglioma (Glomus Jugulare Tumor) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Paraganglioma (Glomus Jugulare Tumor) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Paraganglioma (Glomus Jugulare Tumor) overview
Abnormal growth of chromaffin cells, a type of nerve cell found throughout the body leads to paraganglioma also known as glomus jugulare tumor. It is a rare form of neuroendocrine tumor. These tumors can be found in adrenal glands or outside of it especially in carotid artery. Cause is idiopathic. Headache, high blood pressure, faster pulse rate, sweating is some of the commonly seen symptoms. Paragangliomas can be either malignant or benign in nature and genetic mutations are believed to be one of the causes. Diagnosed by physical examination, urine test, blood catecholamine test, PET scan and other radiographic tests. If malignant only preventive or symptomatic care provided majorly beta-blockers if blood pressure is high. If cancerous chemo followed by radiation surgical procedure to remove the tumor.
For a complete picture of PTSR and LoA scores for drugs in Paraganglioma (Glomus Jugulare Tumor), buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
